Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Iressa

- PMLiVE

AstraZeneca announces major expansion of Canadian research footprint

The investment includes the creation of 500 jobs and a new rare disease research hub

EU flag

European Commission grants AstraZeneca three new approvals

The indications are for adults with liver and lung cancers, and chronic lymphocytic leukaemia

- PMLiVE

AstraZeneca/Sanofi’s Beyfortus shows consistent protection against RSV disease in infants

RSV is the most common cause of infant respiratory infections, including pneumonia

- PMLiVE

AstraZeneca and MSD report final overall survival results from prostate cancer study

The combination treatment increased the current patient survival rate by over seven months

- PMLiVE

AstraZeneca’s Evusheld not recommended by NICE for COVID-19 prevention

The agency said there is not enough evidence of the drug’s effectiveness against current variants

- PMLiVE

AstraZeneca progresses application for $360m Ireland manufacturing site

The investment is expected to create around 100 highly skilled jobs

- PMLiVE

AstraZeneca’s heart failure treatment approved for expanded use in EU

Chronic heart failure is the leading cause of hospitalisation for those over the age of 65

- PMLiVE

AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer

Around 210,000 people worldwide are diagnosed with the disease each year

- PMLiVE

MIT researchers develop AI model to detect future lung cancer risk

Lung cancer is the leading cause of cancer in the US, accounting for 1.7 million deaths globally in 2020

- PMLiVE

AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer

Breast cancer is one of the leading causes of cancer-related deaths globally, with more than two millions cases diagnosed in 2020

- PMLiVE

AstraZeneca joins UK pilot evaluating AI-based lung cancer diagnosis system

More than 43,000 people are diagnosed with lung cancer every year in the UK

- PMLiVE

AstraZeneca’s severe asthma treatment approved in EU for self-administration

Most healthcare providers, patients and caregivers are able to successfully use the pre-filled pen

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links